Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc. ACOR

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.


Recent & Breaking News (NDAQ:ACOR)

Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors

Business Wire February 21, 2017

Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016

Business Wire February 14, 2017

Watch These 5 Huge Put Purchases In Friday Trade

Benzinga.com  February 10, 2017

Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301

Business Wire February 9, 2017

Acorda Therapeutics to Present at Two Investor Conferences in February

Business Wire February 3, 2017

Acorda to Host Conference Call to Discuss Fourth Quarter 2016 on February 14, 2017

Business Wire January 31, 2017

Research Reports Initiation on Biotech Stocks -- Jazz Pharma, Infinity Pharma, Acorda Therapeutics, and Ultragenyx Pharma

PR Newswire January 30, 2017

Acorda Announces 2016 AMPYRA Net Sales and 2017 Financial Guidance at J.P. Morgan Healthcare Conference

Business Wire January 9, 2017

January Will Feature Some Of The Market's Most Influential Events

Benzinga.com  December 30, 2016

Acorda Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference

Business Wire December 28, 2016

12 Biggest Mid-Day Losers For Monday

Benzinga.com  December 19, 2016

Biotech Stocks on Investors' Radar -- Northwest Biotherapeutics, ACADIA Pharma, Acorda Therapeutics, and Ultragenyx Pharma

PR Newswire December 5, 2016

Acorda Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

Business Wire November 22, 2016

Mid-Day Market Update: Headwaters Surges On Acquisition News; Cubic Shares Slide

Benzinga.com  November 21, 2016

Mid-Morning Market Update: Markets Open Higher; Symantec To Acquire Lifelock

Benzinga.com  November 21, 2016

15 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  November 21, 2016

Acorda to Discontinue Development of Dalfampridine for Treatment of Post-Stroke Walking Difficulties

Business Wire November 21, 2016

Acorda Therapeutics to Present at the Stifel 2016 Healthcare Conference

Business Wire November 9, 2016

Acorda Provides Financial and Pipeline Update for Third Quarter 2016

Business Wire October 27, 2016

Acorda to Host Conference Call to Discuss Third Quarter 2016 on October 27, 2016

Business Wire October 17, 2016